Balversa 4 mg Alternative – Erdarixen (Erdafitinib) 4 mg Tablet | Everest Pharmaceuticals
Erdarixen 4 mg (Erdafitinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Balversa (Janssen). It belongs to the FGFR inhibitor class and is used in selected FGFR-altered urothelial cancer.
Active ingredient: Erdafitinib
Strength: 4 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.